CSIMarket
 


Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 
 

RCKT's Income from Cont. Operations Growth by Quarter and Year

Rocket Pharmaceuticals Inc 's Income from Cont. Operations results by quarter and year




RCKT Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -66.72 -44.25 -29.08
III Quarter September -61.90 -57.76 -50.12 -25.04
II Quarter June -65.70 -54.40 -34.53 -24.66
I Quarter March -58.34 -42.98 -40.18 -19.86
FY   -185.94 -221.86 -169.08 -98.64



RCKT Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Rocket Pharmaceuticals Inc in the third quarter 2023 recorded loss from continued operations of $ -61.90 millions.

According to the results reported in the third quarter 2023, Rocket Pharmaceuticals Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Rocket Pharmaceuticals Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




RCKT Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Rocket Pharmaceuticals Inc 's third quarter 2023 Income from Cont. Operations $ -61.90 millions RCKT's Income Statement
Rocket Pharmaceuticals Inc 's third quarter 2022 Income from Cont. Operations $ -57.76 millions Quarterly RCKT's Income Statement
New: More RCKT's historic Income from Cont. Operations Growth >>


RCKT Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Rocket Pharmaceuticals Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RCKT's III. Quarter Q/Q Income from Cont. Operations Comment
Although Rocket Pharmaceuticals Inc in the III. Quarter 2023 revealed loss from continued operations of $ -61.90 millions, it should be mentioned, that those numbers show improvement relative to the -65.70 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Rocket Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Rocket Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RCKT's III. Quarter Q/Q Income from Cont. Operations Comment
Although Rocket Pharmaceuticals Inc in the III. Quarter 2023 showed loss from continued operations of $ -61.90 millions, management point out, that current results show slight up side compare to the -65.70 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Rocket Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Rocket Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Rocket Pharmaceuticals Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -252.66 $ -248.52 $ -237.22 $ -221.86 $ -199.39
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Rocket Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -253 millions in the Sep 30 2023 period.
The results are detiriorating as the cumulative loss from continued operations is becoming larger from $ -248.52 millions in TTM ending quarter Jun 30 2023 and $ -191.749 millions for the twelve months ending in the quarter a year ago.

Rocket Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Rocket Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -253 millions in the Sep 30 2023 period.
The business is detiriorating as the cumulative loss from continued operations is getting bigger from $ -248.52 millions for the period from Jun 30 2023 to Sep 30 2022 and $ -191.749 millions for the twelve months ending in the quarter Sep 30 2022.

Rocket Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
RCKT's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for RCKT's Competitors
Income from Cont. Operations Growth for Rocket Pharmaceuticals Inc 's Suppliers
Income from Cont. Operations Growth for RCKT's Customers

You may also want to know
RCKT's Annual Growth Rates RCKT's Profitability Ratios RCKT's Asset Turnover Ratio RCKT's Dividend Growth
RCKT's Roe RCKT's Valuation Ratios RCKT's Financial Strength Ratios RCKT's Dividend Payout Ratio
RCKT's Roa RCKT's Inventory Turnover Ratio RCKT's Growth Rates RCKT's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
United Therapeutics Corporation11.83%$ 11.826 millions
Edwards Lifesciences Corporation11.70%$ 11.703 millions
Vertex Pharmaceuticals Inc11.26%$ 11.263 millions
Iqvia Holdings Inc 7.07%$ 7.067 millions
Medpace Holdings Inc 6.85%$ 6.850 millions
Prestige Consumer Healthcare Inc 5.41%$ 5.406 millions
Resmed Inc 4.25%$ 4.249 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com